Clinical

Dataset Information

0

A Retrospective Observational Study in the Expanded Access Program of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer (BEACON EAP Follow-up Study )

ABSTRACT: Primary outcome(s): Overall survival

DISEASE(S): Braf V600e-mutant Metastatic Colorectal Cancer

PROVIDER: 33441 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
| S-EPMC7260582 | biostudies-literature
Unknown CTNI-60. PRELIMINARY RESULTS OF BINIMETINIB AND ENCORAFENIB IN ADULTS WITH RECURRENT BRAF V600E-MUTATED HIGH-GRADE GLIOMA
| S-EPMC9660876 | biostudies-literature
Unknown Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
| S-EPMC9271503 | biostudies-literature
Unknown Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.
| S-EPMC11096001 | biostudies-literature
Unknown Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.
| S-EPMC11537293 | biostudies-literature
Unknown Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.
| S-EPMC11415680 | biostudies-literature
Unknown Encorafenib plus cetuximab for the treatment of <i>BRAF-V600E</i>-mutated metastatic colorectal cancer.
| S-EPMC9260564 | biostudies-literature
Unknown Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
| S-EPMC12873207 | biostudies-literature
Unknown Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care.
| S-EPMC7653122 | biostudies-literature
Unknown Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
| S-EPMC12680272 | biostudies-literature